To compare lung injury among non-small cell lung cancer (NSCLC) patients treated with IMRT or proton therapy as revealed by <sup>18</sup>F-FDG post-treatment uptake and to determine factors predictive for clinically symptomatic radiation pneumonitis.
The present study aims to assess the performance of 18F-FDG PET-CT on mediastinal staging of non-small cell lung cancer (NSCLC) in a location with endemic granulomatous infectious disease.
Metabolic information obtained through <sup>18</sup>F-flurodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) is used to evaluate malignancy by calculating the glucose uptake rate, and these parameters play important roles in determining the prognosis of non-small cell lung cancer (NSCLC).
This study aimed to assess the relationship between bone marrow (BM) FDG uptake on PET/CT and serum inflammatory markers and to evaluate the prognostic value of BM FDG uptake for predicting clinical outcomes in non-small cell lung cancer (NSCLC) patients.
<b>Conclusion:</b><sup>18</sup>F-FDG PET/CT metabolic parameters combined with clinicopathological data demonstrated moderate diagnostic efficacy in predicting <i>EGFR</i> mutation status and were associated with prognosis in mutant and wild-type <i>EGFR</i> non-small-cell lung cancer (NSCLC), thus providing a reference for individualized targeted molecular therapy.
The predictive value of <sup>18</sup>F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
<sup>18</sup>FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns.
EGFR-TKI treatment sensitivity prediction in NSCLC using <sup>18</sup> F-FDG PET/CT imaging significantly correlated with CD147-mediated glucose metabolic regulation via the Akt/mTOR-dependent pathway.
<sup>18</sup>F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Assessment of nodal involvement in non-small-cell lung cancer with 18F-FDG-PET/CT: mediastinal blood pool cut-off has the highest sensitivity and tumour SUVmax/2 has the highest specificity.
We aimed to evaluate the relationships between circulating tumor cells (CTCs) or plasma cell-free DNA (cfDNA) on one side and a comprehensive range of <sup>18</sup>F-FDG PET/CT-derived parameters on the other side in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC).
We evaluated the reproducibility and predictive value of texture parameters and existing parameters of 18F-FDG PET/CT images in Stage I non-small-cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT).
Information feedback of <sup>18</sup>F-FDG PET/CT computer imaging combined with tumor markers on recurrence and metastasis of non-small cell lung cancer.
We present a case of non-small cell lung cancer with myocardial and pericardial metastases obscured by physiologic F-FDG cardiac uptake but detected with the investigational PET radiotracer (4S)-4-(3-F-fluoropropyl)-L-glutamate (F-FSPG), which targets a pathway associated with glutathione biosynthesis.
<sup>18</sup>F-FDG PET/MRI and <sup>18</sup>F-FDG PET/CT show an equivalently high diagnostic performance for T and N staging in patients suffering from NSCLC.
The aim of this study was to investigate the relationship between whole-tumor CT perfusion and FDG PET/CT parameters in non-small cell lung cancer (NSCLC).
Two hundred thirty-four consecutive patients who were performed pretreatment F-FDG PET/computed tomography and pathologically diagnosed as NSCLC were assessed retrospectively.